Development and validation of a pharmacokinetic model of flucloxacillin for dosing in patients with impaired renal functio

Completed

• Conditions: 10004018; impaired renal function; ierfunctiestoornissen

• Registration Number: NL-OMON41120
• Lead Sponsor: Atrium Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

- adults treated with oral or intravenous flucloxacillin
- normal and impaired renal function expressed as MDRD and corrected for BSA (body surface area)

Exclusion Criteria

- patients younger than 18 years of age;
- legally incapable patients;
- contra-indication or allergy to the treatment with flucloxacillin;
- pregnant patients;
- patients receiving dialysis.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Main study endpoint is the development of a PK-model for dosing of<br /><br>flucloxacillin in patients with impaired renal function.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoint is the predictive value of the model for dosing of<br /><br>flucloxacillin in patients with impaired renal function.</p><br>